跳至主要内容
临床试验/CTRI/2026/03/105224
CTRI/2026/03/105224尚未招募不适用

To Study Serum Chromogranin A Levels in Heart Failure with Preserved Ejection Fraction as a Prognostic Marker – A Longitudinal Observational Study

JNMC BELAGAVI1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2026年3月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
80
试验地点
1

研究概览

简要总结

  • Heart Failure with Preserved Ejection Fraction (HFpEF) lacks robust prognostic biomarkers.

  • Chromogranin A (CgA) reflects sympathetic activation and myocardial neurohormonal stress.

  • This study evaluates:

  • Prognostic significance of serum CgA in HFpEF

  • Incremental value over NTproBNP

  • 80 HFpEF patients will be followed for 6 months.

  • Primary outcomes: Readmission and Mortality.

  • Statistical evaluation using ROC analysis and multivariate regression.

  • Aim: To determine whether CgA can improve risk stratification in HFpEF.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Diagnosed HFpEF 2D Echo EF 50% or more NTproBNP more than 300 pg/ml Provided informed consent.

排除标准

  • Chronic Kidney Disease Chronic Liver Disease Neuroendocrine tumors.

研究者

发起方
JNMC BELAGAVI
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr. Rekha S Patil

JNMC BELAGAVI

研究点 (1)

Loading locations...

相似试验